Venlafaxin Liconsa 300 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

venlafaxin liconsa 300 mg depottablett

laboratorios liconsa s.a. - venlafaxinhydroklorid - depottablett - 300 mg - laktosmonohydrat hjälpämne; venlafaxinhydroklorid 339,4 mg aktiv substans; mannitol hjälpämne

Suiseng Coli C vet Injektionsvätska, suspension Sverige - svenska - Läkemedelsverket (Medical Products Agency)

suiseng coli c vet injektionsvätska, suspension

laboratorios hipra, s.a. - clostridium novyi, typ b, alfa-toxoid; clostridium perfringens typ c beta toxoid; escherichia coli lt enterotoxoid, stam cp-324, inaktiverat; escherichia coli, stam cp-216, f4ab fimbrieadhesin, inaktiverad; escherichia coli, stam cp-216, f5 fimbrieadhesin, inaktiverad; escherichia coli, stam cp-324, f4ac fimbrieadhesin, inaktiverad; escherichia coli, stam cp-324, f6 fimbrieadhesin, inaktiverad - injektionsvätska, suspension - escherichia coli lt enterotoxoid, stam cp-324, inaktiverat 55 %er70 aktiv substans; escherichia coli, stam cp-324, f6 fimbrieadhesin, inaktiverad 80 %er25 aktiv substans; escherichia coli, stam cp-324, f4ac fimbrieadhesin, inaktiverad 78 %er70 aktiv substans; clostridium novyi, typ b, alfa-toxoid 1,23 rp aktiv substans; aluminiumoxid, hydratiserad 0,5 g adjuvans; clostridium perfringens typ c beta toxoid 1,05 rp aktiv substans; escherichia coli, stam cp-216, f4ab fimbrieadhesin, inaktiverad 65 %er60 aktiv substans; escherichia coli, stam cp-216, f5 fimbrieadhesin, inaktiverad 79 %er50 aktiv substans; ginsengextrakt 4 mg adjuvans - svin

Halofusol 0,5 mg/ml Oral lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

halofusol 0,5 mg/ml oral lösning

laboratorios karizoo s.a. - halofuginonlaktat - oral lösning - 0,5 mg/ml - bensoesyra hjälpämne; halofuginonlaktat 0,609 mg aktiv substans; tartrazin hjälpämne - nöt

Mhyosphere PCV ID Europeiska unionen - svenska - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - grisar - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Isoflutek Vet 1000 mg/g Inhalationsånga, vätska Sverige - svenska - Läkemedelsverket (Medical Products Agency)

isoflutek vet 1000 mg/g inhalationsånga, vätska

laboratorios karizoo s.a. - isofluran - inhalationsånga, vätska - 1000 mg/g - isofluran 1000 mg aktiv substans - burfåglar, chinchilla, hamster, hund, häst, iller, katt, marsvin, mus, reptiler, råtta

Suiseng Diff/A Europeiska unionen - svenska - EMA (European Medicines Agency)

suiseng diff/a

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - grisar - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Azacitidine Lorien 25 mg/ml Pulver till injektionsvätska, suspension Sverige - svenska - Läkemedelsverket (Medical Products Agency)

azacitidine lorien 25 mg/ml pulver till injektionsvätska, suspension

laboratorios lorien s.l. - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - azacitidin 25 mg aktiv substans; mannitol hjälpämne

Porcivac Ery Parvo Injektionsvätska, emulsion Sverige - svenska - Läkemedelsverket (Medical Products Agency)

porcivac ery parvo injektionsvätska, emulsion

laboratorios syva s.a. - erysipelothrix rhusiopathiae, serotyp 2, stam se-9, inaktiverad; porcint parvovirus, stam pvp-7, inaktiverat - injektionsvätska, emulsion - montanide isa 201 vg 0,91 g adjuvans; tiomersal hjälpämne; porcint parvovirus, stam pvp-7, inaktiverat 320 - 5120 hit aktiv substans; erysipelothrix rhusiopathiae, serotyp 2, stam se-9, inaktiverad 7,4 - 61 elisa e aktiv substans - svin

Fentanyl Basi 50 mikrogram/ml Injektionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fentanyl basi 50 mikrogram/ml injektionsvätska, lösning

laboratorios basi - industria farmaceutica s.a. - fentanylcitrat - injektionsvätska, lösning - 50 mikrogram/ml - fentanylcitrat 78,5 mikrog aktiv substans

Cristalmina 10 mg/ml Kutan spray, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

cristalmina 10 mg/ml kutan spray, lösning

laboratorios salvat s.a. - klorhexidindiglukonat - kutan spray, lösning - 10 mg/ml - klorhexidindiglukonat 10 mg aktiv substans